VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML

Treatment of acute myeloid leukemia (AML) remains challenging. Enhancement of anti-tumor responses by blocking negative immune regulators is a promising strategy for novel effective leukemia therapeutics. V-domain Ig suppressor of T-cell activation (VISTA) is a recently defined negative regulator me...

Full description

Bibliographic Details
Main Authors:	Liru Wang, Bei Jia, David F. Claxton, W Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Seema Naik, Muhammad R. Khawaja, Jeff Sivik, Junyan Han, Raymond J. Hohl, Hong Zheng
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2018-09-01
Series:	OncoImmunology
Subjects:	acute myeloid leukemia (aml) vista programmed cell death protein 1 (pd-1) immunotherapy
Online Access:	http://dx.doi.org/10.1080/2162402X.2018.1469594

Similar Items

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia
by: Liuluan Zhu, et al.
Published: (2017-06-01)

Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
by: Randolph J. Noelle, et al.
Published: (2023-09-01)

Downregulation of CD73 associates with T cell exhaustion in AML patients
by: Yaxian Kong, et al.
Published: (2019-04-01)

Investigation of HEG1, VISTA (VSIR) and PD-L1 expression levels in malignant mesothelioma by immunohistochemical methods and their relationship with histological subtypes
by: Medine Dicleli, et al.
Published: (2024-03-01)

Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia
by: Jianshan Mo, et al.
Published: (2023-02-01)

Comprehensive Transcriptomic Analysis of VISTA in Acute Myeloid Leukemia: Insights into Its Prognostic Value
by: Simona Pagliuca, et al.
Published: (2022-11-01)

Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors
by: Paulina Chmiel, et al.
Published: (2023-06-01)

Maintenance therapy for AML after allogeneic HCT
by: Rahul K. Nayak, et al.
Published: (2022-08-01)

CD26lowPD-1+ CD8 T cells are terminally exhausted and associated with leukemia progression in acute myeloid leukemia
by: Huarong Zhou, et al.
Published: (2023-06-01)

VISTA, PDL-L1, and <i>BRAF</i>—A Review of New and Old Markers in the Prognosis of Melanoma
by: Andreea Cătălina Tinca, et al.
Published: (2022-01-01)

VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma
by: Aida Jlassi, et al.
Published: (2024-04-01)

Oncogenic Roles Of A Histone Methyltransferase SETDB2 In AML1-ETO Positive AML
by: Mu G, et al.
Published: (2020-02-01)

PD-1 and beyond to Activate T Cells in Cutaneous Squamous Cell Cancers: The Case for 4-1BB and VISTA Antibodies in Combination Therapy
by: Quentin Wright, et al.
Published: (2021-07-01)

Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma
by: Shuxin Huang, et al.
Published: (2022-11-01)

Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia
by: Seema Naik, et al.
Published: (2024-01-01)

A review of treatment options employed in relapsed/refractory AML
by: Mohamed Zakee Mohamed Jiffry, et al.
Published: (2023-12-01)

The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma
by: Nour el Imane Issam Salah, et al.
Published: (2023-08-01)

Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML
by: F. Brauneck, et al.
Published: (2021-01-01)

VISTA: A Target to Manage the Innate Cytokine Storm
by: Mohamed A. ElTanbouly, et al.
Published: (2021-02-01)

The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers
by: Emily Hensler, et al.
Published: (2022-07-01)

Effective Dendritic Cell-based Immunotherapeutic Vaccines for Acute Myeloid Leukemia (AML)
by: Maryam Nourizadeh, et al.
Published: (2014-11-01)

An interesting case of chronic myeloid leukemia (CML) with T315I mutation raising suspicion of de novo AML, a diagnostic conundrum
by: Phool Iqbal, et al.
Published: (2023-05-01)

Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML
by: Jiaxiong Tan, et al.
Published: (2020-02-01)

A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors
by: Shawn Iadonato, et al.
Published: (2023-12-01)

Bimodal expression of RHOH during myelomonocytic differentiation: Implications for the expansion of AML differentiation therapy
by: Sylvie Galiègue‐Zouitina, et al.
Published: (2021-05-01)

Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors
by: Shawn Iadonato, et al.
Published: (2024-01-01)

VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma
by: Hai-Xia He, et al.
Published: (2021-01-01)

CD123 Is Consistently Expressed on <i>NPM1</i>-Mutated AML Cells
by: Vincenzo Maria Perriello, et al.
Published: (2021-01-01)

CircNFIX knockdown inhibited AML tumorigenicity by the miR-876-3p/TRIM31 axis
by: Lifang Huang, et al.
Published: (2022-12-01)

High VISTA expression is linked to a potent epithelial-mesenchymal transition and is positively correlated with PD1 in breast cancer
by: Ibtissam Rezouki, et al.
Published: (2023-04-01)

Case Report: CMML in Young Age which Transformed to AML
by: Wilujeng Anggraini, et al.
Published: (2023-11-01)

Geographic Heterogeneity of the AML1-ETO Fusion Gene in Iranian Patients with Acute Myeloid Leukemia
by: Saeedeh Ghazaey Zidanloo, et al.
Published: (2014-10-01)

PD1 expression on bone marrow T‐cells in newly diagnosed Egyptian AML patients: Correlation with hematological parameters, aberrant antigens expression, and response to induction therapy
by: Noha Bassiouny, et al.
Published: (2020-07-01)

Minimal residual disease monitoring via AML1-ETO breakpoint tracing in childhood acute myeloid leukemia
by: Xiaoyan Chen, et al.
Published: (2021-08-01)

MDSD Multi-Plataforma: Más Allá de la Vista Funcional
by: Juan Camilo Jiménez, et al.
Published: (2016-05-01)

NPM 1 Mutations in AML—The Landscape in 2023
by: Naman Sharma, et al.
Published: (2023-02-01)

Combined Assessment of Immune Checkpoint Regulator VISTA on Tumor-Associated Immune Cells and Platelet-to-Lymphocyte Ratio Identifies Advanced Germ Cell Tumors with Higher Risk of Unfavorable Outcomes
by: Rafał Pęksa, et al.
Published: (2021-04-01)

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
by: Franziska Brauneck, et al.
Published: (2021-11-01)

KRAS (G12D) Cooperates with AML1/ETO to Initiate a Mouse Model Mimicking Human Acute Myeloid Leukemia
by: Shanmin Zhao, et al.
Published: (2014-01-01)

Biomarkers as targets for CAR-T/NK cell therapy in AML
by: Ruonan Shao, et al.
Published: (2023-06-01)